Journal of Hepatology最新文献

{"title":"Reply to correspondence on “Acute kidney Injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting”","authors":"Mitra K. Nadim, John A. Kellum, François Durand","doi":"10.1016/j.jhep.2024.10.025","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.025","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors’ contribution</h2>MKN, JAK and FD wrote the manuscript and revised it</section></section><section><section><h2>Financial support</h2>none</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"34 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stigma Among Chinese Speaking Patients with Non-alcoholic Fatty Liver Disease and Their Providers","authors":"Zobair M. Younossi, Maria Stepanova","doi":"10.1016/j.jhep.2024.10.026","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.026","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Abbreviations</h2>Metabolic dysfunction-associated steatotic liver disease (MASLD), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH)”<u>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a very common liver disease in the general population with an especially high</u></section></section><section><section><h2>Uncited reference</h2>2.; 3.; 4.; 15..</section></section><section><section><h2>Funding</h2>No funding was received for this work.</section></section><section><section><h2>Declaration of Competing Interest</h2>ZMY has received research funding and/or serve as consultant to Intercept, CymaBay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, Ipsen, AstraZeneca, Siemens, Madridgal, Merck and Abbott</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"93 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial","authors":"Sunjae Lee, Bethlehem Arefaine, Neelu Begum, Marilena Stamouli, Elizabeth Witherden, Merianne Mohamad, Azadeh Harzandi, Ane Zamalloa, Haizhuang Cai, Roger Williams, Mike Curtis, Lindsey A. Edwards, Shilpa Chokshi, Adil Mardinoglu, Gordon Proctor, David Moyes, Mark J. McPhail, Debbie L. Shawcross, Mathias Uhlen, Saeed Shoaie, Vishal C. Patel","doi":"10.1016/j.jhep.2024.09.046","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.09.046","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;Cirrhosis complications are often triggered by bacterial infections with multidrug-resistant organisms. Alterations in the gut and oral microbiome in decompensated cirrhosis (DC) influence clinical outcomes. We interrogated: (i) gut and oral microbiome community structures, (ii) virulence factors (VFs) and antimicrobial resistance genes (ARGs) and (iii) oral-gut microbial overlap in patients with differing cirrhosis severity.&lt;h3&gt;Methods&lt;/h3&gt;15 healthy controls (HC), 26 stable cirrhosis (SC), 46 DC, 14 acute-on-chronic liver failure (ACLF) and 14 with severe infection without cirrhosis (NLS) participated. Metagenomic sequencing was undertaken on paired saliva (S) and faecal (F) samples. ‘Salivatypes’ and ‘enterotypes’ based on genera clustering were assessed against cirrhosis severity and clinical parameters. VFs and ARGs were evaluated in oral and gut niches, and distinct resistotypes identified.&lt;h3&gt;Results&lt;/h3&gt;Salivatypes and enterotypes revealed a greater proportion of pathobionts with concomitant reduction in autochthonous genera with increasing cirrhosis severity and hyperammonaemia. Increasing overlap between oral and gut microbiome communities was observed in DC and ACLF vs SC and HCs, independent of antimicrobial, beta-blocker and acid suppressant therapies. Two distinct gut microbiome clusters [ENT2/ENT3] harboured genes encoding for the phosphoenolpyruvate:sugar phosphotransferase system (PTS) system and other VFs in DC and ACLF. Substantial ARGs (oral: 1,218 and gut: 672) were detected [575 common to both sites]. The cirrhosis resistome was distinct, with three oral and four gut resistotypes identified, respectively.&lt;h3&gt;Discussion&lt;/h3&gt;The degree of oral-gut microbial community overlap, frequency of VFs and ARGs all increment significantly with cirrhosis severity, with progressive dominance of pathobionts and loss of commensals. Despite similar antimicrobial exposure, patients with DC and ACLF have reduced microbial richness compared to NLS, supporting the additive pathobiological effect of cirrhosis.&lt;h3&gt;Impact and implications&lt;/h3&gt;This research underscores the crucial role of microbiome alterations in the progression of cirrhosis in an era of escalating multidrug resistant infections, highlighting the association and potential impact of increased oral-gut microbial overlap, virulence factors, and antimicrobial resistance genes on clinical outcomes. These findings are particularly significant for patients with decompensated cirrhosis and acute-on-chronic liver failure, as they reveal the intricate relationship between microbiome alterations and cirrhosis complications. This is relevant in the context of multidrug-resistant organisms and reduced oral-gut microbial diversity that exacerbate cirrhosis severity, drive hepatic decompensation and complicate treatment. For practical applications, these insights could guide for cirrhosis patients the development of targeted microbiome-based therapeutics and personal","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"23 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing functional cure rates after nucleo(s)tide analogue withdrawal: is peg-IFN the answer?","authors":"Edo J. Dongelmans, Milan J. Sonneveld, Harry L.A. Janssen","doi":"10.1016/j.jhep.2024.10.019","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.019","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Clinical trial number:</h2>not applicable.</section></section><section><section><h2>Conflict of interest:</h2>Edo Dongelmans has no conflicts of interests; Milan Sonneveld receives speakers’ fees and research support from Roche, Bristol Myers Squibb, Gilead Sciences, and Fujirebio. Harry Janssen received grants from: Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is consultant for: Aligos, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences, Griffols.</section></section><section><section><h2>Financial support:</h2>No funding was received for this article.</section></section><section><section><h2>Author contributions:</h2>Edo Dongelmans, MD (Conceptualization: Equal; Writing – original draft: Lead). Milan Sonneveld, MD, PhD (Conceptualization: Equal; Writing – review &amp; editing: Equal). Harry L.A. Janssen, MD, PhD (Conceptualization: Equal; Supervision: Lead; Writing – review &amp; editing: Equal).</section></section><section><section><h2>Data availability statement:</h2>not applicable.Nucleo(s)tide analogues (NA) are well-tolerated and highly effective in suppressing HBV DNA in patients with chronic hepatitis B (CHB). Unfortunately, the risk of HCC may persist, particularly in patients who do not achieve functional cure, defined as loss of HBsAg loss. As functional cure is rarely achieved with NA mono-therapy,¹ alternative strategies are explored to increase HBsAg clearance.Recent trials with novel compounds suggest that immune modulatory agents likely play a</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"115 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142452534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: “A gold mine of information from a deep dive into the liver transcriptome” [J Hepatol (2024) 540-542]","authors":"Wajahat Zafar Mehal","doi":"10.1016/j.jhep.2024.10.003","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.003","url":null,"abstract":"It has come to our attention that the following text should have been included in the ‘Financial support’ section of this article: “Dr. Mehal has an appointment at the West Haven VA Medical Center and this work was supported by a US Department of Veterans Office of Research &amp; Development with grant BX003259-05A1”. We apologise for any inconvenience caused.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"124 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142486476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is MetALD an independent risk factor of all-cause mortality? A meta-analysis of 164,694 individuals from the real world","authors":"Zheng Li, Yali Shen, Zhiping Li, Dan Cao, Yue Hu","doi":"10.1016/j.jhep.2024.10.022","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.022","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Zheng Li, Yue Hu, and Dan Cao contributed to the study conception and design. Zheng Li, Yali Shen, Zhiping Li, Dan Cao, and Yue Hu performed data acquisition, analysis, and interpretation. Zheng Li, Yali Shen, and Zhiping Li wrote the initial draft, Yue Hu and Dan Cao revised the manuscript. All authors reviewed and approved the final manuscript.</section></section><section><section><h2>Data availability statement</h2>The data that support the findings of this study are all included in this article and the supplementary material.</section></section><section><section><h2>Funding</h2>This work was jointly supported by the National Natural Science Foundation of China (Grant No. 82272746), and the Medical Science and Technology Project of Sichuan Provincial Health Commission (Grant No. 21PJ135).</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare no conflicts of interest.</section></section><section><section><h2>Acknowledgements</h2>The authors would like to thank Yaqin Zhao, Ningjing Lei (Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China), Xi Chen, Qing Liu, and Shihong Nie (Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China) for their valuable help in data collection and data analysis.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"66 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142452507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","authors":"Sohyun Hwang, Seonjeong Woo, Beodeul Kang, Haeyoun Kang, Jung Sun Kim, Sung Hwan Lee, Chang Il Kwon, Dong Soo Kyung, Hwang-Phill Kim, Gwangil Kim, Chan Kim, Hong Jae Chon","doi":"10.1016/j.jhep.2024.10.020","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.020","url":null,"abstract":"<h3>Background &amp; Aims</h3>Recent advances in molecular profiling enable the identification of potential therapeutic targets for biliary tract cancer (BTC). However, in patients with BTC, molecular profiling is hindered by challenges in obtaining adequate tissue samples. Circulating tumor DNA (ctDNA) may offer an alternative to tissue-based analysis. Here we aimed to assess the concordance between ctDNA and tissue genomic profiling in a large cohort of Asian patients with advanced BTC, and to evaluate the feasibility of liquid biopsy in BTC treatment.<h3>Methods</h3>This study included patients with systemic treatment-naive advanced BTC, treated at CHA Bundang Medical Center between January 2019 and December 2022. We enrolled patients with available baseline tissue-based next-generation sequencing (NGS), and sufficient plasma samples for ctDNA analysis (AlphaLiquid®100 from IMBdx).<h3>Results</h3>Among 102 enrolled patients, 49.0% had intrahepatic cholangiocarcinoma, 26.5% extrahepatic cholangiocarcinoma, and 24.5% gallbladder cancer. The concordance between intra-patient ctDNA and tumor tissue mutations revealed a sensitivity of 84.8%, and positive predictive value of 79.4%. ctDNA revealed targetable alterations in 34.3% of patients—including <em>FGFR2</em> fusion, <em>IDH1</em> mutation, microsatellite instability (MSI)-high, <em>ERBB2</em> amplification, <em>PIK3CA</em> mutations, <em>BRCA1/2</em> mutations, and <em>MET</em> amplification. Notably, a novel <em>FGFR2-TNS1</em> fusion was identified in ctDNA, which was not targeted in the tissue NGS panel. A high maximum somatic variant allele frequency in ctDNA was associated with poor prognosis after gemcitabine/cisplatin-based chemotherapy, in terms of both overall survival (<em>p</em> = 6.9 × 10⁻⁶) and progression-free survival (<em>p</em> = 3.8 × 10⁻⁷).<h3>Conclusions</h3>Among patients with advanced BTC, ctDNA-based genotyping showed acceptable concordance with tissue genomic profiling. Liquid biopsy using ctDNA could be a valuable complement to tissue-based genomic analysis in BTC.<h3>Impact and implications</h3>Our study is the first large-scale investigation of the clinical utility of liquid biopsy, focusing on ctDNA, as an alternative to conventional tumor tissue analysis, among Asian patients with advanced BTC. The results demonstrated acceptable concordance between analysis of ctDNA versus tissue for identifying therapeutic targets and potentially actionable genetic alterations. This indicates that ctDNA analysis can provide critical insights regarding advanced BTC treatment, particularly in cases where it is challenging to obtain or analyze tumor tissue.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"221 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142452530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author’s Reply: Pyroptosis in Liver Failure: A Twisted Firestarter","authors":"Vlad TARU, Thomas REIBERGER","doi":"10.1016/j.jhep.2024.10.021","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.021","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Author contributions:</h2>VT and TR both drafted and reviewed the reply letter for intellectual content.</section></section><section><section><h2>Financial support:</h2>none.</section></section><section><section><h2>Declaration of Competing Interest:</h2>VT is funded by the Christian-Doppler Research Association and Boehringer Ingelheim RCV GmbH &amp; Co KG (CD10271603); Romanian Ministry of Research, Innovation and Digitalization (PNRR/2022/C9/MCID/I8).TR received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore &amp; Associates; speaking honoraria from Abbvie, Echosens, Gilead, Intercept/Advanz Pharma, Roche, MSD, W. L. Gore &amp; Associates;</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"20 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142452531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid hormone receptor-β analogs for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)","authors":"Vlad Ratziu, Thomas S. Scanlan, Eveline Bruinstroop","doi":"10.1016/j.jhep.2024.10.018","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.018","url":null,"abstract":"The association between suboptimal thyroid function ((sub)clinical hypothyroidism or low normal thyroid function) and the metabolic syndrome and metabolic dysfunction-associated steatotic liver disease (MASLD) is clearly established. Furthermore, in MASLD, thyroid hormones have low intracellular concentrations and the activation of the thyroid hormone receptor (THR) is reduced. Administration of thyroid hormone has been shown to reduce liver triglycerides by stimulating fatty acid disposal through lipophagy and beta-oxidation, and to lower LDL-cholesterol. As thyroid hormone exerts it’s effects in many different organs, including heart and bone, several drug candidates have been developed acting as selective thyromimetics for the THR-β nuclear receptor with potent and targeted liver actions. Importantly, these compounds have reduced affinity for the THR-α nuclear receptor and tissue distribution profiles that differ from endogenous thyroid hormones thereby reducing unwanted cardiovascular side effects. The most advanced compound, resmetirom, is an oral drug that demonstrated, in a large phase 3 trial in MASH patients, the ability to remove liver fat, reduce aminotransferase levels and improve atherogenic dyslipidemia with a good tolerability profile. This translated into histological improvement that led to accelerated approval of this drug for active fibrotic steatohepatitis, a milestone achievement as a first MASH drug.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"4 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142450256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients","authors":"Yen-Chun Liu, Yun-Fan Liaw","doi":"10.1016/j.jhep.2024.10.017","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.017","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors contribution:</h2>Yen-Chun Liu: manuscript draftingYun-Fan Liaw: Study concept, manuscript revision</section></section><section><section><h2>Grant support</h2>This study was supported by grants from Chang Gung Medical Research Fund (CMRPG1N0111) and the Prosperous Foundation, Taipei, Taiwan</section></section><section><section><h2>Conflict of interest</h2>The authors have no financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"33 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}